Pituitary enlargement following ipilimumab without long term endocrine dysfunction.
Sign Up to like & getrecommendations! Published in 2021 at "Current problems in cancer"
DOI: 10.1016/j.currproblcancer.2021.100710
Abstract: Ipilimumab, a monoclonal antibody against CTLA-4, is used in the treatment of melanoma and renal cell cancer. Hypophysitis is one of the more common adverse events, usually presenting with headache, pituitary enlargement and hypopituitarism, mostly… read more here.
Keywords: without long; enlargement; long term; ipilimumab without ... See more keywords